Biotechnology stocks and sector-related exchange traded funds stood out Friday after regulators breathed new life into Biogen (NasdaqGS: BIIB) and its partner Eisai Co. (ESALY) on a new Alzheimer’s drug candidate. Among the top performing non-leveraged ETFs of Friday, the VanEck Vectors...